Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976284 | 1.00 | MPI (0.33) | MPI | |
| SCHEMBL7715583 | 1.00 | MPI (0.33) | MPI | |
| SCHEMBL6386404 | 0.94 | MPI (0.34) | MPI | |
| SCHEMBL11305111 | 0.87 | BTN3A1 (0.33) | MPI | |
| SCHEMBL29512271 | 0.87 | BTN3A1 (0.33) | MPI | |
| SCHEMBL9698100 | 0.87 | BTN3A1 (0.33) | MPI | |
| SCHEMBL1016010 | 0.87 | BTN3A1 (0.33) | MPI | |
| SCHEMBL3074545 | 0.83 | MPI (0.35) | MPI | |
| Guanidine SCHEMBL9485722 | 0.80 | — | — | |
| SCHEMBL8057 | 0.77 | LMNA (0.41) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613504-A | Adeno-associated virus variant capsids and methods of use thereof | 4D分子治疗有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20230075422-A1 | USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY | BRISTOL-MYERS SQUIBB COMPANY | 2023-03-09 | — | — | US | disclosed |
| US-20220229026-A1 | METHODS OF DETECTING GLYCOGEN AND POLYGLUCAN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-07-21 | — | — | US | disclosed |
| CN-106165175-B | High molecular electrolyte composition and polyelectrolyte membrane, film electrode composite element and the polymer electrolyte fuel cell for using it | 东丽株式会社 | 2019-11-08 | — | — | CN | disclosed |
| US-10103401-B2 | Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same | TORAY INDUSTRIES, INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3131145-B1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | TORAY INDUSTRIES (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| JP-2002360291-A | METHOD FOR SIMPLY AND ARTIFICIALLY SYNTHESIZING B-L-FUCOSE MONOPHOSPHATE | SEAFOOD SUTERA:KK | 2002-12-17 | — | — | JP | disclosed |
| US-5580858-A | Immunosuppressive and tolerogenic modified Lewisx compounds | ALBERTA RESEARCH COUNCIL (CA) | 1996-12-03 | — | — | US | disclosed |
| EP-0591254-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWIS?X AND LEWIS?A COMPOUNDS | GLYCOMED INCORPORATED (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1992022564-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISX AND LEWISA COMPOUNDS | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075422-A1 | USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY | GMDS, GPI, FUCA1 | MPI 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.